Purchase this article with an account.
J Wachtlin, T Behme, H Heimann, MH Foerster; PDT for sub- and Juxtafoveal Choroidal Neovascularizations (CNV) in Patients With Presumed Ocular Histoplasmosis Syndrom (POHS) . Invest. Ophthalmol. Vis. Sci. 2002;43(13):567.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To date only little data is available about follow up and visual acuity of patients which underwent Photodynamic Therapy (PDT) for CNV due to conditions other than AMD. This study examines the visual outcome after PDT with Verteporfin in patients with CNV due to presumed ocular histoplasmosis syndrom (POHS). Methods: In a prospective study, 9 patients with choroidal neovascularization due to POHS underwent PDT treatment with Verteporfin with standard parameters. Follow up examinations were carried out every 3 months including fluorescein angiography and visual acuity assessment with ETDRS charts. Treatment was repeated if fluorescein angiography revealed leakage of the CNV. Results: The average age was 35.7 years (27-49) and the mean follow up interval was 13.4 months (sd = 7.3). 3 patients showed a recurrence of a pre-treated CNV. The median greatest linear dimension of the CNV was 1370 microns and an average of 1.7 treatments were given to the patients. The mean visual acuity improvement was +1.7 ETDRS lines (-1 to +5). 6 patients (66.6%) showed visual acuity improvement of 2 or more lines, in 3 eyes (33.3%) visual acuity was unchanged (+/- 1 line) and none of the patients showed a decrease of 2 or more lines. No side effects with relevance for visual acuity have been observed. Conclusion: PDT for treatment of CNV due to POHS seems to be a safe procedure. In all cases CNV was successfully treated with PDT with stabilisation or even improvement of visual acuity and reduction of fluorescein leakage during a long follow up period. We regard PDT as the treatment of choice in patients with sub- and juxtafoveal CNV due to presumed ocular histoplasmosis syndrome.
This PDF is available to Subscribers Only